Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Mgmt tried to hide this from the public....so, instead of

<< Previous

Bullboard Posts

Next >>

Post by luvhorseson Oct 09, 2020 3:23pm

161 Views

Post# 31696884

Mgmt tried to hide this from the public....so, instead of

putting this out in a separate news release, they decided to include it in with another one hoping that it gets lost :

Update on South Korea COVID-19 trial

Due to a lack of sufficiently ill patients, which is a direct result of a highly successful government initiated pandemic mitigation strategy, the company has decided to close the investigator-led South Korea trial.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 8, 2024)